Role of intravenous iron therapy in children with severe acute malnutrition with iron deficiency anemia

Abhijeet Sharad Naik; Nilesh Vitthalrao Ahire; Suhas Vasantrao Patil; Suvarna Abhijeet Naik

doi:10.18203/2349-3291.ijcp20263303

Authors

Abhijeet Sharad Naik Department of Paediatrics, MPGIMER, MUHS Nashik, Maharashtra, India
Nilesh Vitthalrao Ahire Department of Paediatrics, MPGIMER, MUHS Nashik, Maharashtra, India
Suhas Vasantrao Patil Department of Paediatrics, MPGIMER, MUHS Nashik, Maharashtra, India
Suvarna Abhijeet Naik Department of Clinical Trial Unit, CHAKRA, MUHS Nashik, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20263303

Keywords:

Severe acute malnutrition, Iron deficiency anemia, Intravenous iron sucrose therapy, Pediatric anemia, Hematological outcomes

Abstract

Background: Iron deficiency anemia (IDA) is the most common micronutrient deficiency among children under five years of age, with severe acute malnutrition (SAM). The coexistence of SAM and IDA increases the risk of impaired growth, developmental delay, recurrent infections, hospitalization, and mortality. Oral iron supplementation is the standard treatment but is often limited in children with SAM because of poor tolerance, reduced absorption. Intravenous (IV) iron sucrose may provide rapid correction of iron deficiency; however, evidence regarding its safety and efficacy in this population is limited. This study evaluated the safety and efficacy of IV iron sucrose therapy in children with SAM and IDA.

Methods: This observational study was conducted in children under five years, with SAM and diagnosed with IDA. Sample size was 65, after stabilization, eligible and clinically stable children received IV iron sucrose in 50ml normal saline administered over 30 minutes on days 7^th, 10^th, and 13^th as per Ganzoni’s formula. Follow-up assessments were performed on day 14, 30, and 45, including anthropometry and hematological parameters. Adverse events were monitored.

Results: A total of 65 children with SAM and IDA were enrolled. Mean hemoglobin (Hb) increased from 6.19 g/dL at baseline to 9.62 g/dL at follow-up. Serum ferritin improved from 28.8 µg/L to 157.49 µg/L. Red cell indices showed significant improvement. No serious adverse reactions were reported.

Conclusions: IV iron sucrose therapy is a safe and effective for correcting IDA in children with SAM, especially where oral iron therapy is poorly tolerated.

References

Dipasquale V, Cucinotta U, Romano C. Acute malnutrition in children: pathophysiology, clinical effects, and treatment. Nutrients. 2020;12(8):2413.

UNICEF guidelines 2024. Facility based management of children with SAM. Available at: https://data.unicef.org. Accessed on 3 June 2026.

Guerrant RL, Oriá RB, Moore SR, Oriá MO, Lima AA. Malnutrition as an enteric infectious disease with long-term effects on child development. Nutr Rev. 2008;66(9):487-505.

Janz TG, Johnson RL, Rubenstein SD. Anemia in the emergency department: evaluation and treatment. Emerg Med Pract. 2013;15(11):1-15.

National Heart, Lung, and Blood Institute (NHLBI). What is anemia? 2022. Available at: https://www.nhlbi.nih.gov. Accessed on 3 June 2026.

National Heart, Lung, and Blood Institute (NHLBI). Causes and risk factors. 2022. Available at: https://www.nhlbi.nih.gov. Accessed on 3 June 2026.

Elghetany MT, Schexneider KI, Banki K. Henry's clinical diagnosis and management by laboratory methods. 23rd ed. Elsevier. 2017;559-605.

McInerny TK. American Academy of Pediatrics textbook of pediatric care. 2nd ed. Elk Grove Village, IL: American Academy of Pediatrics. 2017.

UNICEF. The state of food security and nutrition 2023. UNICEF Data; 2023. Available at: https://data.unicef.org. Accessed on 3 June 2026.

Khan MS, Khan A, Hussain U, Khan A, Tahir M, Afnan B, et al. Effectiveness and Safety of Intravenous Iron Sucrose Therapy in Children with Iron Deficiency Anemia. Education. 2022;21:13-8.

International Institute for Population Sciences (IIPS) and ICF. National Family Health Survey (NFHS-5), 2019-21: India. Mumbai: IIPS. 2021.

Dwivedi D, Singh V, Singh J, Sharma S. Study of anemia in children with severe acute malnutrition. J Nepal Paediatr Soc. 2017;37(3):250-3.

Girum T, Kote M, Tariku B, Bekele H. Survival status and predictors of mortality among severely acute malnourished children under 5 years of age admitted to stabilization centers in Gedeo Zone: a retrospective cohort study. Ther Clin Risk Manag. 2017;13.

National Heart, Lung, and Blood Institute (NHLBI). What is anemia? 2022. Available at: https://www.nhlbi.nih.gov. Accessed on 3 June 2026.

Cohen CT, Powers JM. Intravenous iron therapy in pediatrics: who should get it and when is the right time? Hematology Am Soc Hematol Educ Program. 2023; 2023(1):630-5.

Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia. 2015;2015:763576.

Goldman L, Schafer A, editors. Goldman-Cecil Medicine. 25th ed. Elsevier/Saunders. 2016: 1052-1059.

Litton E, Xiao J. Safety and efficacy of intravenous iron therapy in reducing requirement of allogenic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:1-10.

Bhutta ZA, Berkley JA, Bandsma RHJ, Kerac M, Trehan I, Briend A. Severe childhood malnutrition. Nat Rev Dis Primers. 2017;3:17067.

Thakur N, Chandra J, Pemde H, Singh V. Anemia in severe acute malnutrition. Nutrition. 2014;30(4):440-2.

Rodgers GM, Gilreath JA. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. Acta Haematol. 2019;142(1):13-20.

Gómez-Ramírez S, Bisbe E, Shander A, Spahn DR, Muñoz M. Management of Perioperative Iron Deficiency Anemia. Acta Haematol. 2019;142(1):21-9.

Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr. 2001;131(2S-2):568S-79S.

Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721-41.

Ellwanger J, Ziliotto M, Kulmann-Leal B, Chies J. Iron deficiency and soil-transmitted helminth infection: classic and neglected connections. Parasitol Res. 2022;121(3):1-5.

Demosthenous C, Vlachaki E, Apostolou C, Eleftheriou P, Kotsiafti A, Vetsiou E, et al. Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology. 2019;24(1):426-38.

Nelson WE, Kliegman R, W J, Behrman RE, Robert CT, Shah SS, et al. Nelson textbook of paediatrics. 22nd ed. Vol. 2. 2024: 2925-2952.